Connection

JAMES C YAO to Sirolimus

This is a "connection" page, showing publications JAMES C YAO has written about Sirolimus.
Connection Strength

2.740
  1. Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. Cancer Res. 2013 Mar 01; 73(5):1449-53.
    View in: PubMed
    Score: 0.312
  2. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012 Mar 15; 18(6):1777-89.
    View in: PubMed
    Score: 0.292
  3. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011 Dec; 96(12):3741-9.
    View in: PubMed
    Score: 0.284
  4. mTOR inhibition, a potential novel approach for bronchial carcinoids. Endocr Relat Cancer. 2011 Jun; 18(3):C15-8.
    View in: PubMed
    Score: 0.275
  5. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10; 364(6):514-23.
    View in: PubMed
    Score: 0.271
  6. Perspectives in the development of novel treatment approaches. Tumori. 2010 Sep-Oct; 96(5):858-73.
    View in: PubMed
    Score: 0.263
  7. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010 Jan 01; 28(1):69-76.
    View in: PubMed
    Score: 0.249
  8. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med. 2009 Jan 08; 360(2):195-7.
    View in: PubMed
    Score: 0.235
  9. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008 Sep 10; 26(26):4311-8.
    View in: PubMed
    Score: 0.229
  10. Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned. Oncologist. 2013; 18(5):525-32.
    View in: PubMed
    Score: 0.079
  11. The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. Cancer Res. 2012 Nov 15; 72(22):5683-91.
    View in: PubMed
    Score: 0.076
  12. New strategies for advanced neuroendocrine tumors in the era of targeted therapy. Clin Cancer Res. 2012 Apr 01; 18(7):1830-6.
    View in: PubMed
    Score: 0.073
  13. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011 Dec 10; 378(9808):2005-2012.
    View in: PubMed
    Score: 0.072
  14. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 2011 Nov; 141(5):1728-37.
    View in: PubMed
    Score: 0.017
  15. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer. 2008 Mar; 15(1):257-66.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.